[1]章志福,汤礼宾,麦丽兰,等.左旋咪唑联合甲泼尼龙治疗成人原发免疫性血小板减少症疗效观察*[J].陕西医学杂志,2020,49(7):881-883888.[doi:DOI:10.3969/j.issn.10007377.2020.07.031]
　ZHANG Zhifu,TANG Libin,MAI Lilan,et al.Therapeutic effect of levamisole combined with methylprednisolone in treatment of adult primary immune thrombocytopenia[J].,2020,49(7):881-883888.[doi:DOI:10.3969/j.issn.10007377.2020.07.031]
点击复制

左旋咪唑联合甲泼尼龙治疗成人原发免疫性血小板减少症疗效观察*
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
49
期数:
2020年7期
页码:
881-883888
栏目:
药物与临床
出版日期:
2020-07-05

文章信息/Info

Title:
Therapeutic effect of levamisole combined with methylprednisolone in treatment of adult primary immune thrombocytopenia
作者:
章志福1; 汤礼宾2; 麦丽兰3; 孙洪波1; 刘军民1; 罗 伟1
1. 广东省深圳市龙华区人民医院血液科(深圳 518109); 2. 广东省深圳市龙华区人民医院产科(深圳 518109); 3. 广东省深圳市龙华区人民医院景龙社康(深圳 518109)
Author(s):
ZHANG Zhifu; TANG Libin; MAI Lilan; et al.
Department of Hematology,Longhua District People's Hospital,Shenzhen City,Guangdong Province(Shenzhen 518109)
关键词:
成人原发免疫性血小板减少症;  左旋咪唑;  甲泼尼龙;  联合治疗;  血小板减少;  不良反应
Keywords:
Adult primary immune thrombocytopenia;  Levamisole;  Methylprednisolone;  Combined treatment;  Thrombocytopenia;  Untoward effect
分类号:
R558
DOI:
DOI:10.3969/j.issn.10007377.2020.07.031
文献标志码:
A
摘要:
目的:探讨左旋咪唑联合甲泼尼龙在成人原发免疫性血小板减少症(ITP)中的治疗效果与应用价值。方法:以58例成人原发免疫性血小板减少症患者为研究对象,随机分为试验组(29例)和对照组(29例),试验组予以左旋咪唑联合甲泼尼龙治疗,对照组予以单纯甲泼尼龙治疗。在治疗后2周对比试验组及对照组的治疗效果、不良反应发生情况。结果:试验组患者完全反应20例(68.96%)、有效7例(24.13%)、无效2例(6.89%),总有效率为93.09%。对照组患者完全反应11例(37.93%)、有效10例(34.48%)、无效8例(27.58%),总有效率为62.42%。试验组治疗效果显著优于对照组(P<0.05)。此外,在试验组中新诊断ITP总有效率为92.86%,持续性ITP总有效率为90%,持续性ITP总有效率为60%。两组患者的肝肾功能损害、消化道出血、低钾血症、低钙血症、柯兴氏征、感染等不良反应发生率无明显差异。结论:左旋咪唑联合甲泼尼龙可安全有效治疗成人原发免疫性血小板减少症,值得在临床应用。
Abstract:
Objective:To study the therapeutic effect and application value of levamisole combined with methylprednisolone in the treatment of adult primary immune thrombocytopenia. Methods: A total of 58 patients with adult primary immune thrombocytopenia were recruited. All the patients were randomly divided into experimental group(29 patients)and control group(29 patients). The patients in experimental group were treated with levamisole combined with methylprednisolone. The patients in control group were treated with only methylprednisolone. The therapeutic effect and adverse effects were compared between the experimental group and the control group two weeks after treatment. Results: There were 20 cases of CR(68.96%)in experimental group,with 7 case of R(24.13%)and 2 cases of NR(6.89%). The OR rate in experimental group was 93.09%. In the control group,the CR,R and NR cases number were 11(37.93%),10(34.48%)and 8(27.58%),with a total OR of 62.42%. The therapeutic effect of the experimental group was significantly better than that of the control group. Besides,in the experimental group the OR rate of the new ITP,continuous ITP and chronic ITP were 92.86%,90% and 60%. The differences of adverse effects including liver and kidney damage,hemorrhage of digestive tract,hypokalemia,hypocalcemia,Cushing's syndrome and infection between two groups were not significant. Conclusion: Levamisole combined with methylprednisolone was a safe and effective treatment for adult primary immune thrombocytopenia,which could be promoted in clinic.

参考文献/References:

[1] Liu XG,Bai XC,Chen FP,et al. Chinese guidelines for treatment of adult primary immune thrombocytopenia[J]. Int J Hematol,2018,107(6):615-623.
[2] Provan D,Newland AC. Current management of primary immune thrombocytopenia[J]. Adv Ther,2015,32(2):875-887.
[3] 中华医学会血液学分会止血与血栓学组. 成人原发免疫性血小板减少症诊断与治疗中国专家共识(2016年版)[J]. 中华血液学杂志,2016,37(2):89-93.
[4] Solomon N,Hayes J. Levamisole: A High Performance Cutting Agent[J]. Acad Forensic Pathol,2017,7(3):469-476.
[5] Shao Y,Li X,Shi J,et al. Cyclosporin combined with levamisole for refractory or relapsed severe aplastic anaemia[J]. Br J Haematol,2013,162(4):552-555.
[6] Rodeghiero F,Ruggeri M. Treatment of immune thrombocytopenia in adults: the role of thrombopoietin-receptor agonists[J]. Semin Hematol,2015,52(1):16-24.
[7] Liu X,Hou Y,Peng J. Advances in immunopathogenesis of adult immune thrombocytopenia[J]. Front Med,2013,7(4):418-424.
[8] Cirasino L,Semeraro S. Goals defining therapy for primary immune thrombocytopenia in adults[J]. Blood Coagul Fibrinolysis,2017,28(4):348-350.
[9] Cheng L,Liu C,Li F,et al. The prediction value of Treg cell subtype alterations for glucocorticoid treatment in newly diagnosed primary immune thrombocytopenia patients[J]. Thromb Res,2019,181(9):10-16.
[10] Mithoowani S,Gregory-Miller K,Goy J,et al. High-dose dexamethasone compared with prednisone for previously untreated primary immune thrombocytopenia: a systematic review and meta-analysis[J]. Lancet Haematol,2016,3(10):e489-e496.
[11] 张显胜,张爱玲,胡爱国. 甲泼尼龙联用左旋咪唑治疗Graves眼病的临床效果及不良反应探讨[J]. 当代医学,2018,24(8):133-135.
[12] 孙 涛. 生长素联合左旋咪唑对重型肝炎患者血浆细胞因子及肝纤维化指标的影响[J]. 中国医学创新,2019,16(20):102-105.
[13] 刘俊兰. 小剂量环孢素联合左旋咪唑对非重型再生障碍性贫血患者血清血小板水平变化的影响[J]. 实用中西医结合临床,2017,17(16):124-125.
[14] 陈 纯,方建培,黄绍良,等. 硫唑嘌呤、强的松和左旋咪唑联合治疗小儿难治性血小板减少性紫癜[J]. 广东医学,2002,23(1):89-90.
[15] 张正义,马洪建,张夏玮,等. 大剂量地塞米松冲击治疗成人不同分期原发免疫性血小板减少症的近期疗效观察[J]. 临床合理用药杂志,2018,11(28):43-45.
[16] Hou Y,Feng Q,Xu M,et al. High-dose dexamethasone corrects impaired myeloid-derived suppressor cell function via Ets1 in immune thrombocytopenia[J]. Blood,2016,127(12):1587-1597.

备注/Memo

备注/Memo:
*广东省深圳市龙华区科技创新专项(2017年第二批医疗卫生项 目)(2017123)
更新日期/Last Update: 2020-07-28